Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Chronic Idiopathic Urticaria
NCT02166151Phase 3Unknown
- Sponsor
- Rabin Medical Center
- Start
- Jul 2014
- Primary completion
- Jun 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of omalizumab in chronic idiopathic urticaria (CIU), sponsored by Rabin Medical Center. Status: unknown.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NCT02166151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02166151.